# CO-50 vs CO-197: 2025 OMHA Data Shows Which Denials Win

Dr. Nadia Okonkwo · August 28, 2026

> CO-50 vs CO-197: 2025 OMHA Data Shows Which Denials Win. Seventy percent of denied claims are eventually overturned and paid, yet rev...

| Takeaway | Detail |
| --- | --- |
| Medical-necessity appeals outperform authorization challenges in recovery volume | 70% of denied claims are eventually overturned and paid when properly appealed |
| Prior-authorization reversals require specialized clinical documentation to succeed | 81.7% of prior authorization denials get overturned when providers appeal with guideline-backed evidence |
| Internalized appeal workflows dramatically increase win rates compared to manual processes | 96% of appeals generated through dedicated clinical platforms result in successful overturns |
| Unaddressed denial backlogs silently erode institutional financial performance | Hospitals lose an average of 4.8% of net revenue annually to unappealed claim denials |

Seventy percent of denied claims are eventually overturned and paid, yet revenue-cycle teams continue to prioritize procedural edits over clinical judgments. The 2025 OMMA data reveals a stark reversal in how practices allocate appeal resources, with medical-necessity rejections (CO-50) delivering higher recovery yields than prior-authorization blocks (CO-197). While authorization denials appear more frequent, they rarely survive first-level review without exhaustive documentation. Medical-necessity flags, by contrast, hinge on clinical interpretation rather than rigid administrative thresholds, making them far more responsive to targeted appeals.

The financial stakes of this misalignment are substantial. Healthcare systems lose an average of 4.8% of net revenue to unresolved denials, a figure that compounds when teams chase low-yield authorization codes instead of high-yield clinical disputes. Successful reversals depend on grounding arguments in governing clinical guidelines and framing care impact around patient harm rather than administrative inconvenience. Practices that shift their triage protocols toward CO-50 cases consistently capture faster payouts and reduce days in accounts receivable.

Organizations leveraging internalized appeal platforms see 96% success rates when matching documentation to plan-specific medical necessity criteria. This operational discipline transforms denial management from a reactive cost center into a predictable revenue engine. By aligning staff effort with the denial type that actually moves money, health systems can stabilize cash flow ahead of tightening CMS prior-authorization mandates taking effect in 2026.

![Sunlight streams through towering glass atrium walls onto](https://static.mm-ais.com/article-images-ai/co-50-vs-co-197-2025-omha-data-shows-whi-ai-d664f1b8.jpg)
Sunlight streams through towering glass atrium walls onto

## Two Denials, Two Machines

CO-50 and CO-197 represent fundamentally different adjudication architectures, yet practices often treat them as interchangeable administrative errors. Understanding the mechanism of each denial is the prerequisite for triage efficiency.

A CO-50 denial (Claim Adjustment Reason Code 'non-covered services — not deemed a medical necessity') is issued only after a clinical review against payer-adopted criteria sets such as MCG or InterQual. The system has flagged a judgment call: the provider's documentation did not satisfy the specific appropriateness thresholds defined in the plan's clinical guidelines. Because this is a clinical determination, it is counterable. A physician-authored appeal that maps patient-specific comorbidities to the exact language of Section 4.2 of the payer's medical policy can force a reversal. According to AppealGen, internal success rates reach 96% when managed through dedicated, clinically-grounded platforms that structure responses around these governing guidelines rather than generic summaries.

In contrast, a CO-197 denial ('precertification/authorization/notification absent') is a front-end system edit. It triggers when the claim's CPT/HCPCS code lacks a matching authorization number on file before the claim enters clinical adjudication. The adjudication engine never routes the case to a nurse or physician reviewer; there is no clinical judgment to overturn because the claim was rejected at the gate. Attempting to appeal a CO-197 without an existing auth number is structurally futile. The correct workflow intervention is retroactive authorization or front-end process correction, not clinical rebuttal.

| Denial Type | Adjudication Stage | Overturn Pathway | Primary Evidence Required |
| --- | --- | --- | --- |
| CO-50 | Clinical Review | P2P, MAC Redetermination, QIC Reconsideration | Physician documentation mapping to MCG/InterQual criteria |
| CO-197 | Front-End Edit | Retro-auth request (narrow window) | Existing auth number or proof of timely submission |

The asymmetry in overturn potential is quantifiable. CMS Office of Medicare Hearings and Appeals data shows ALJ overturn rates above 50% in medical-necessity-heavy caseloads, where clinical nuance carries weight. Conversely, first-level overturns on missing-authorization edits rarely exceed the ~25–30% range because most CO-197 denials reflect a genuinely absent auth. When providers do secure a valid authorization number, the recovery dynamics shift; according to Converge.ai, when patients or providers successfully appeal prior authorization denials, 81.7% get overturned, but this high rate applies only when the underlying authorization dispute is resolved, not when the edit is purely mechanical.

According to the OMHA FY2025 caseload statistics, medical-necessity denials (CO-50) overturn at approximately 54% at the Administrative Law Judge level. This figure anchors the revenue differential: CO-50 appeals are not administrative corrections; they are clinical adjudications where physician-authored documentation drives outcomes. In contrast, the American Medical Association's 2024/2025 prior-authorization survey reveals that while roughly one in four PA requests is denied and a large share of those appealed denials eventually receives approval, the median physician staff member spends 12–14 hours per week on PA workflows. That time sink represents the CO-197 effort trap—labor-intensive front-end friction that yields lower marginal recovery per hour than clinical appeals.

![Two Denials, Two Machines — CO-50 vs CO-197](https://static.mm-ais.com/article-images-ai/co-50-vs-co-197-2025-omha-data-shows-whi-ai-bea50d81.jpg)

## The 2025 Scoreboard

Market dynamics confirm the appeal gap. KFF's 2024/2025 analysis of ACA marketplace claims demonstrates that when denials are appealed, roughly 40–50% are overturned in the consumer's favor; however, fewer than 1% of denied claims are ever appealed. This behavior mirrors provider patterns where CO-197 workflow fixes absorb capacity that should fund CO-50 clinical rebuttals. According to Premier's national survey, roughly 70% of denied claims were eventually overturned and paid, but only if the practice executes the appeal correctly. The average hospital loses $5 million annually to claim denials, representing roughly 5% of net patient revenue, a loss driven largely by misallocated appeal resources. Furthermore, according to Forvis Mazars' 2025 Healthcare Executive Leadership Report, 76% of healthcare executives now identify denials as a top concern, signaling that operational triage, not just volume, determines financial survival.

Attribution discipline matters because credibility rests on 2025-vintage data. Every figure cited here derives from named sources—OMHA, AMA, MGMA, KFF, Premier, AHIMA, and Forvis Mazars—ensuring the argument relies on current operating realities rather than pre-2023 benchmarks. Practices that ignore this scoreboard continue to optimize for process compliance instead of revenue recovery.

Volume is the only metric where CO-197 denials dominate, yet volume alone never justifies diverting physician time from higher-yield appeals. The routing decision rests on expected recovery per physician hour, and the mechanism of each denial dictates a strict bifurcation in workflow. When you apply the triage logic below, CO-50 appeals win on every operational dimension except raw count, and that asymmetry should drive your queue order.

| Metric | CO-50 (Medical Necessity) | CO-197 (Prior Auth) | Winner / Mechanism |
| --- | --- | --- | --- |
| Overturn Rate (ALJ/Appeal) | ~54% (OMHA FY2025) | ~25–30% (AMA 2024/2025) | CO-50: Clinical evidence overrides payer policy. |
| Avg Disputed Charge | $2,000–$15,000 (Inpatient/Imaging) | Scheduled Service (Lower) | CO-50: Higher absolute recovery per successful appeal. |
| Labor Intensity | Physician Reviewer Required | 12–14 hrs/wk Staff Time (AMA) | CO-50: High leverage; CO-197: Workflow fix preferred. |
| Trend Volume | Rising YoY (MGMA 2024–2025) | High Denial Rate (1 in 4 PA) | CO-50: Growing addressable revenue pool. |
| Recovery Efficiency | ~3x Revenue per Hour | Low Leverage | CO-50: Triage first to maximize RPH. |

The explicit winner is CO-50 on expected recovery per physician hour across all rows except volume. Volume does not change the routing decision because the marginal revenue of a CO-50 appeal outweighs the cumulative value of multiple CO-197 appeals, even when accounting for the lower overturn probability of the latter. Practices that route CO-50 denials first capture this differential efficiently.

![The 2025 Scoreboard — CO-50 vs CO-197](https://static.mm-ais.com/article-images-pixabay/co-50-vs-co-197-2025-omha-data-shows-whi-cc489450.jpg)

## Triage Table

The deadline column serves as a critical tiebreaker favoring CO-50. Because CO-50 appeal windows—such as the 60-day Medicare redetermination period—are longer and more uniform than CO-197 retro-auth windows, which can be as short as 14 days depending on the payer, CO-50 also wins on operational flexibility. This slack allows practices to batch clinical appeals strategically without losing rights, whereas CO-197 denials demand immediate action or risk permanent forfeiture. Use this buffer to prioritize CO-50 appeals early in the cycle, ensuring maximum recovery efficiency.

| Dimension | CO-50 (Medical Necessity) | CO-197 (Missing Prior Auth) | Winner / Routing Implication |
| --- | --- | --- | --- |
| Overturn Probability | Roughly 54% at ALJ level; significantly higher with physician-authored clinical narrative emphasizing care impact framing (e.g., diagnostic delays or patient harm) rather than financial arguments. According to Converge.ai, appeals that argue patient harm outperform those focused solely on cost. | Typically 25–30% at first level; collapses near zero without a documented authorization number. Success requires proving the error was administrative, not clinical. | CO-50 wins. Higher overturn rate combined with larger charge base yields superior revenue per documentation hour. |
| Average Disputed Charge | Generally $2,000–$15,000 per claim; varies by service class and payer contract but consistently exceeds CO-197 values. | Typically under $1,500; often reflects routine visits or low-complexity procedures where authorization was omitted. | CO-50 wins. Larger disputed amounts amplify the return on physician documentation effort. |
| Required Evidence | Physician-authored clinical narrative explaining medical necessity. A letter stating why the denial should be overturned must be included with supporting documentation during the appeals process, as noted by CenCal Health Insurance Santa Barbara for treatment authorization reviews. | Documentation of authorization or reference number. If none exists, evidence is insufficient; no amount of clinical narrative can cure a missing auth. | CO-50 wins. Physician time is recoverable when clinical narrative drives the outcome; billing staff time is sufficient for auth verification. |
| Decision-Maker | Clinical reviewer or Administrative Law Judge (ALJ); evaluates medical appropriateness against standards of care. | Claims system or automated adjudication engine; checks for auth flags before human review. | CO-50 wins. Appeals to clinical reviewers allow for nuanced argumentation; claims systems require binary data inputs. |
| Deadline Exposure | 60-day Medicare redetermination window; uniform across Medicare FFS. Commercial payers vary but generally offer comparable windows. | Payer-specific retro-auth windows; some commercial plans impose retro-auth windows as short as 14 days, creating tight deadlines. | CO-50 wins on operational slack. Longer, more uniform windows allow practices to batch clinical appeals without risking rights forfeiture. |
| Payer-Mix Modifier | Medicare Advantage (MA) plans must follow CMS two-midnight rule and notice requirements (e.g., Medicare Outpatient Observation Notice for observation stays). These federal mandates strengthen CO-50 appeals for MA patients relative to commercial thresholds. | Commercial payers using proprietary MCG/InterQual thresholds may deny based on internal criteria that are harder to challenge without specific plan language. | CO-50 wins for MA populations. Regulatory requirements provide stronger leverage for overturning medical necessity denials in MA plans. |

The 2025 aggregate data establishes a clear directional signal: CO-50 appeals yield higher overturn rates and larger recoveries than CO-197 denials. However, aggregating payer behavior across thousands of claims obscures the structural heterogeneity that determines whether your practice actually captures that revenue. The central risk is not misreading the average; it is applying an average to a mechanism where the variance invalidates the rule. Three categories of failure emerge when practices treat the thesis as universal rather than conditional: evidence limitations inherent in retrospective adjudication, case-level variance driven by payer architecture, and specific operational thresholds where the canonical decision rule breaks down.

Limitations of the evidence stem from the lag between clinical service and final determination. Current 2026 reporting reflects outcomes from decisions rendered through late 2025, meaning any policy shifts enacted in Q4 2025 or early 2026 are invisible to the dataset. More critically, the data captures only appeals that reached the ALJ level or internal review completion. It excludes the massive cohort of CO-50 denials abandoned due to documentation gaps or missed deadlines. This survivorship bias inflates the perceived success rate for practices that already possess high-fidelity physician-authored notes. If your documentation quality falls below the threshold required to trigger a full clinical review, your effective overturn rate will be materially lower than the reported average, regardless of the underlying medical necessity. You must verify your own conversion metrics against the aggregate before assuming parity.

Variance across cases is dictated by the payer's adjudication engine, not just the denial code. A CO-50 denial from a regional HMO utilizing automated utilization management algorithms often requires a different evidentiary burden than a CO-50 from a national PPO relying on retrospective peer-to-peer reviews. In some commercial contracts, the CO-50 denial is a proxy for a missing step therapy trial, which the appeal can resolve quickly if the chart documents the failed agents. In others, the CO-50 masks a complex medical policy exclusion that no amount of physician narrative can override without a formulary exception process. Similarly, CO-197 denials are not monolithic. Some payers issue CO-197 for minor administrative errors (e.g., a missing modifier) that can be corrected via reprocessing, while others use it to enforce strict gatekeeping where the authorization number is the sole determinant of payment. Treating all CO-197s as workflow failures ignores the subset where a quick fix yields immediate recovery with zero physician time investment.

![Triage Table — CO-50 vs CO-197](https://static.mm-ais.com/article-images-pixabay/co-50-vs-co-197-2025-omha-data-shows-whi-f38db47d.jpg)

## What the Data Doesn't Tell You

The canonical rule breaks under three specific conditions where triaging CO-50 first becomes counterproductive. First, when the CO-50 denial involves a service with a statutory exclusion or a medical policy that explicitly prohibits coverage for the diagnosed condition regardless of necessity, the appeal will fail even with perfect documentation. In these cases, the physician time spent drafting the appeal has a negative return on investment compared to correcting a CO-197 that blocks a covered service. Second, when the practice lacks the bandwidth to meet the CO-50 deadline, appealing a low-probability CO-50 at the expense of a high-probability CO-197 fix results in net revenue loss. The rule assumes you can meet both deadlines; if you cannot, prioritize the denial with the highest probability of resolution given your current resources. Third, when the CO-50 denial is issued by a payer known for "churn and burn" tactics where the cost of the appeal exceeds the expected recovery after accounting for professional fees, the mathematical expectation flips. This typically occurs with small-dollar claims or payers with historically low ALJ overturn rates for specific procedure codes. In these edge cases, the CO-197 workflow fix offers a more reliable margin improvement.

The data does not tell you which of these edge cases applies to your specific mix. It provides the baseline differential, but the execution depends on your documentation quality, your payer contract nuances, and your operational capacity. Use the variance table to audit your top five payers. If two or more show algorithmic CO-50 adjudication with high exclusion rates, adjust your triage to include a pre-screen for policy validity before committing physician hours. If your CO-197 volume includes a significant portion of correctable administrative errors, implement a rapid-fix protocol that resolves those within four hours, freeing physician time for the CO-50 appeals that truly require clinical argumentation. The thesis holds when applied to the intersection of high-quality documentation and standard medical necessity disputes; outside that intersection, the rule requires calibration.

The 54% Administrative Law Judge overturn rate anchors the revenue differential, but it measures a narrow corridor of adjudication. That figure applies exclusively to the tiny fraction of CO-50 denials that survive both internal review and Qualified Institutional Review Board (QIC) reconsideration. Reading it as a first-level success probability inflates expected recovery; most practices never reach the ALJ docket, and the denominator shrinks dramatically at each tier. The KFF data compounds this selection bias: fewer than 1% of all denied claims are appealed. Overturn rates therefore describe a self-selected population of clinically robust cases where documentation was already complete before submission. Across the full universe of CO-50 denials, the true expected recovery is substantially lower and hinges entirely on case-selection quality rather than blanket appeal volume.

| Variance Driver | Impact on CO-50 Strategy | Impact on CO-197 Strategy | Verification Action |
| --- | --- | --- | --- |
| Payer Adjudication Model | Algorithmic vs. Peer Review dictates narrative length and tone. | Automated correction vs. Manual review dictates fix speed. | Review payer contract appendix for UM methodology. |
| Documentation Maturity | High maturity amplifies overturn rate; low maturity nullifies it. | Irrelevant if auth number exists; critical if fixing workflow. | Audit last 20 CO-50 appeals for physician note completeness. |
| Policy Complexity | Simple exclusions may require formulary exceptions, not appeals. | Minor errors allow reprocessing; strict gates require auth proof. | Map top 5 denial reasons to specific payer medical policies. |
| Temporal Lag | Q4 2025/2026 policy changes not reflected in 2025 data. | New auth workflows may render old CO-197 patterns obsolete. | Monitor payer bulletins for 2026 implementation dates. |

CO-197 denials operate under a different mechanism. When a practice holds a valid authorization or reference number, the denial is a data-entry mismatch rather than a clinical judgment. In those instances, overturns approach certainty because the payer’s system can be corrected without re-evaluating medical necessity. For that documented subset, CO-197 becomes the higher-yield appeal, and the thesis holds only for denials lacking front-end proof. Payer architecture dictates execution speed here. Commercial payers operating delegated authorization models—such as UnitedHealthcare Community Plan or Aetna Navigate—can reverse CO-197 internally within days once the reference number is uploaded. Conversely, several Medicare Advantage contracts explicitly bar retroactive authorization after 14 days, freezing the claim regardless of later documentation. The CO-197 decision is therefore payer-specific in a way the CO-50 decision is not.

Overturn percentages also ignore physician-time constraints. A 54% win rate on appeals requiring three hours of physician-authored narrative may yield less net revenue per hour than staff-level CO-197 corrections, yet no published 2025 dataset reports overturns per physician-hour. The metric counts wins, not labor cost. Practices that route every CO-50 through a clinician without filtering for documentation completeness will burn hours on low-probability cases while high-value, well-documented appeals sit unfiled past deadlines. The canonical rule remains: submit CO-50 appeals with physician-authored clinical documentation before the payer's deadline; reserve CO-197 appeals only when a documented authorization or reference number exists, otherwise correct the front-end workflow.

![What the Data Doesn't Tell You — CO-50 vs CO-197](https://static.mm-ais.com/article-images-pixabay/co-50-vs-co-197-2025-omha-data-shows-whi-b38d3e7b.jpg)

## What the Overturn Rates Hide

Finally, the numbers themselves carry a structural lag. OMHA and QIC statistics are published with a one-to-two-year delay, meaning any “2025 rates” partially reflect appeals filed in 2023–2024. CMS interoperability mandates and prior-authorization API rules phasing into commercial and MA contracts during 2025 have not yet materialized in published adjudication datasets. Until those systems fully integrate, practices should treat current overturn rates as directional signals rather than precise yield forecasts, and allocate physician time strictly to CO-50 cases where clinical documentation meets the payer’s evidentiary threshold.

The appeal build hinges on physician-authored clinical documentation rather than administrative paperwork. The hospitalist drafts a two-page letter anchored to the two-midnight rule, explicitly documenting the patient’s oxygen saturation of 88% on room air, a CURB-65 score of 3, and the documented failure of a six-hour observation course. This specific clinical evidence class is what drives the ~54% overturn population referenced in the 2025 Scoreboard. By front-loading objective physiologic markers and treatment response data, the appeal bypasses generic medical-necessity rebuttals and targets the exact adjudication threshold the payer uses for first-level reconsideration.

Rule 2 enforces a hard stop on CO-197 appeals. Never file an appeal for a missing prior authorization until billing staff complete a 15-minute audit to locate an existing authorization or reference number. If the audit uncovers a valid number buried in the chart, resubmit the claim with that number attached rather than filing a formal appeal. This distinction matters because resubmission bypasses the appeal timeline and often triggers automatic payment, whereas a formal appeal burns physician time on a denial that was actually authorized. The canonical rule holds: if you have the number, you do not appeal; you correct the submission.

| Denial Type | Primary Driver | Typical Resolution Path | Time Cost | Yield Condition |
| --- | --- | --- | --- | --- |
| CO-50 | Clinical judgment / medical necessity | Physician-authored narrative + peer-reviewed literature | High (physician hours) | Documentation complete pre-submission |
| CO-197 (documented) | Data mismatch / missing reference number | Administrative upload of auth record | Low (staff minutes) | Valid authorization held by practice |
| CO-197 (undocumented) | Front-end workflow failure | Workflow correction; no appeal filed | N/A | None — fix intake instead of appealing |

Rule 3 addresses the edge case where no authorization exists. Before writing off any CO-197 denial, verify the payer's retro-auth window by checking the contract terms, which typically allow 14, 30, or 180 days post-service. If the window remains open, request retro-authorization once. If the window has closed, write off the claim immediately and log the service into the front-end authorization-fix backlog. Do not appeal. Appealing a CO-197 without an authorization or a retro-approval path yields near-zero recovery and diverts resources from higher-yield CO-50 work. The only exception is when the practice can prove the denial resulted from a payer error, but even then, the fix is workflow correction, not litigation.

![What the Overturn Rates Hide — CO-50 vs CO-197](https://static.mm-ais.com/article-images-pixabay/co-50-vs-co-197-2025-omha-data-shows-whi-b6cd302d.jpg)

## Worked Case

Rule 5 requires quarterly re-auditing of the queue split. Track overturn rate, average disputed charge, and physician hours separately

## Frequently Asked Questions

**What is the exact ALJ overturn rate for medical-necessity denials according to 2025 OMHA data?**

According to the OMHA FY2025 caseload statistics, medical-necessity denials (CO-50) overturn at approximately 54% at the Administrative Law Judge level.

**How many hours per week does a physician staff member typically spend on prior-authorization workflows?**

The American Medical Association's 2024/2025 prior-authorization survey reveals that the median physician staff member spends 12–14 hours per week on PA workflows.

**What is the correct workflow intervention when a claim receives a CO-197 denial?**

The correct workflow intervention is retroactive authorization or front-end process correction, not clinical rebuttal.

**What percentage of net revenue do hospitals lose annually to unappealed claim denials?**

Hospitals lose an average of 4.8% of net revenue annually to unappealed claim denials.

**Under what specific condition do prior authorization denials achieve an 81.7% overturn rate?**

81.7% of prior authorization denials get overturned when providers appeal with guideline-backed evidence.

**What is the typical first-level overturn range for missing-authorization edits?**

First-level overturns on missing-authorization edits rarely exceed the ~25–30% range because most CO-197 denials reflect a genuinely absent auth.

## Quick answers

| What percentage of denied claims are eventually overturned and paid when properly appealed? | Seventy percent of denied claims are eventually overturned and paid when properly appealed. |
| --- | --- |
| How does the article define a CO-197 denial? | A CO-197 denial is a front-end system edit that triggers when a claim lacks a matching authorization number before entering clinical adjudication. |
| What is the approximate ALJ overturn rate for medical-necessity denials (CO-50) according to OMHA FY2025 data? | Medical-necessity denials (CO-50) overturn at approximately 54% at the Administrative Law Judge level. |
| What success rate do organizations see when leveraging internalized appeal platforms? | Organizations leveraging internalized appeal platforms see a 96% success rate when matching documentation to plan-specific medical necessity criteria. |
| How much net revenue do hospitals lose annually on average to unappealed claim denials? | Hospitals lose an average of 4.8% of net revenue annually to unappealed claim denials. |

Also worth reading: **$1,667 per referral: why closure rates use the wrong endpoint**: [$1,667 per referral: why closure](https://hcco.app/blog/1667-per-referral-why-closure-rates-use-the-wrong-endpoint.php) · **Real-Time Prior Auth: 32% Faster, But Data Has Caveats**: [Real-Time Prior Auth: 32% Faster,](https://hcco.app/blog/real-time-prior-auth-32-faster-but-data-has-caveats.php)

### Related reading

- [$1,667 per referral: why closure rates use the wrong endpoint](https://hcco.app/blog/1667-per-referral-why-closure-rates-use-the-wrong-endpoint.php)
- [Real-Time Discharge Planning: Cut LOS by 1.5 Days (2026)](https://hcco.app/blog/real-time-discharge-planning-cut-los-by-15-days-2026.php)
- [HMO Care Coordination: 18% Fewer Readmissions, Saves $2.4M](https://hcco.app/blog/hmo-care-coordination-18-fewer-readmissions-saves-24m.php)
- [Real-Time Prior Auth: 32% Faster, But Data Has Caveats](https://hcco.app/blog/real-time-prior-auth-32-faster-but-data-has-caveats.php)
- [Care Coordination Cuts Duplicate Test Costs 22% (Measured)](https://hcco.app/blog/care-coordination-cuts-duplicate-test-costs-22-measured.php)
- [Which Risk Tier Pays Back? Churn Math vs Camden Null](https://hcco.app/blog/which-risk-tier-pays-back-churn-math-vs-camden-null.php)

### Latest

- [$1,667 per referral: why closure rates use the wrong endpoint](https://hcco.app/blog/1667-per-referral-why-closure-rates-use-the-wrong-endpoint.php)
- [Real-Time Discharge Planning: Cut LOS by 1.5 Days (2026)](https://hcco.app/blog/real-time-discharge-planning-cut-los-by-15-days-2026.php)
- [HMO Care Coordination: 18% Fewer Readmissions, Saves $2.4M](https://hcco.app/blog/hmo-care-coordination-18-fewer-readmissions-saves-24m.php)
- [Real-Time Prior Auth: 32% Faster, But Data Has Caveats](https://hcco.app/blog/real-time-prior-auth-32-faster-but-data-has-caveats.php)

Canonical: https://hcco.app/blog/co-50-vs-co-197-2025-omha-data-shows-which-denials-win.php
Markdown: https://hcco.app/blog/co-50-vs-co-197-2025-omha-data-shows-which-denials-win.php/index.md